Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

Front Immunol. 2020 May 7;11:762. doi: 10.3389/fimmu.2020.00762. eCollection 2020.

Abstract

Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cell malignancies. To date, more than one hundred different BsAb formats exist, including bispecific T-cell engagers (BiTEs), and new constructs are constantly emerging. Advances in protein engineering have enabled the creation of BsAbs with specific mechanisms of action and clinical applications. Moreover, a better understanding of resistance and evasion mechanisms, as well as advances in the protein engineering and in immunology, will help generating a greater variety of BsAbs to treat various cancer types. This review focuses on T-cell-engaging BsAbs and more precisely on the various BsAb formats currently being studied in the context of B-cell malignancies, on ongoing clinical trials and on the clinical concerns to be taken into account in the development of new BsAbs.

Keywords: BiTE; bispecific T-cell engager; bispecific antibodies; clinical development; concerns; leukemia; lymphoma; myeloma.

Publication types

  • Review